Physician profile
Mark A Haygood
NPI 1073834370
$348,236.46
in general payments reported to CMS, 2019-2025
33 companies · $104K in 2025
The $104K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $34K · 2021: $44K · 2022: $56K · 2023: $51K · 2024: $46K · 2025: $104K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $158K · Consulting Fee: $18K · Travel and Lodging: $13K · Food and Beverage: $12K · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $158,053.75 |
| Consulting Fee | $17,725.00 |
| Travel and Lodging | $12,616.64 |
| Food and Beverage | $11,528.32 |
| Education | $112.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $149,485.69 | 2019-2025 | Ingrezza |
| Abbvie INC. | $120,115.82 | 2021-2025 | |
| Allergan, INC. | $51,213.53 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $17,948.72 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $2,048.91 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,058.48 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $843.93 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $820.46 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $620.62 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $619.03 | 2019-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $580.19 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $495.89 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $397.10 | 2019-2023 | Neurostar Tms Therapy System |
| Lundbeck LLC | $326.48 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $241.63 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $164.87 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Alkermes, INC. | $164.77 | 2019-2025 | Aristada, Lybalvi |
| Stryker Corporation | $150.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $117.87 | 2021-2022 | |
| Adlon Therapeutics L.P. | $117.15 | 2020-2021 | |
| Shire North American Group INC | $111.41 | 2019 | |
| Corium, LLC | $110.46 | 2022-2025 | Azstarys |
| Eisai INC. | $85.47 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $81.46 | 2019-2022 | |
| Owp Pharmaceuticals, INC. | $58.34 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $47.29 | 2019-2020 | |
| Bausch Health US, LLC | $45.65 | 2021-2023 | Wellbutrin, Aplenzin |
| Neos Therapeutics, Lp | $42.61 | 2024-2025 | Adzenys Xr-Odt |
| Tris Pharma INC | $38.79 | 2023-2025 | Dyanavel Xr |
| Acadia Pharmaceuticals INC | $30.13 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $25.40 | 2019 | |
| Alfasigma USA, INC. | $14.59 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.72 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Haygood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.